Results 51 to 60 of about 3,493 (156)

Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood [PDF]

open access: yes, 2019
Heme is a critical danger molecule liberated from hemeproteins in various conditions, including from hemoglobin in hemolytic diseases. Heme may cause thromboinflammatory damage by activating inflammatory and hemostatic pathways, such as complement, the ...
Fløisand, Yngvar   +17 more
core   +1 more source

Thromboinflammation in COVID-19 acute lung injury [PDF]

open access: yes, 2020
Since the initial description in 2019, the novel coronavirus SARS-Cov-2 infection (COVID-19) pandemic has swept the globe. The most severe form of the disease presents with fever and shortness of breath, which rapidly deteriorates to respiratory ...
Beau Mitchell, William
core   +1 more source

Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Ischemic stroke remains a leading cause of death and disability worldwide, and bleeding (particularly intracranial hemorrhage) continues to limit conventional antithrombotic therapy in secondary prevention, even with direct oral anticoagulants.
Federica Ferrari, Roberto Federico Villa
wiley   +1 more source

Periprostatic Adipose Tissue Thromboinflammation Drives Early Neoplastic Alterations in a Rat Model of Mild Metabolic Dysfunction [PDF]

open access: yes, 2022
Emerging evidence links periprostatic adipose tissue (PPAT) inflammation, a consequence of metabolic impairment, to certain features of prostate cancer (PCa) aggressiveness.
AlZaim, Ibrahim
core  

Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy

open access: yesJournal of Innate Immunity
Background: Sepsis-associated coagulopathy specifically refers to widespread systemic coagulation activation accompanied by a high risk of hemorrhage and organ damage, which in severe cases manifests as disseminated intravascular coagulation (DIC), or ...
Xin Wei   +5 more
doaj   +1 more source

Methotrexate‐Induced Drug Hypersensitivity Syndrome Presenting With Acute Cerebral Infarction in End‐Stage Renal Disease: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Methotrexate (MTX) is primarily renally excreted, making patients with end‐stage renal disease (ESRD) highly vulnerable to drug accumulation and toxicity. While severe drug‐induced hypersensitivity syndrome (DIHS) is a known life‐threatening adverse reaction, its association with acute central nervous system complications, specifically ...
Le Mu   +6 more
wiley   +1 more source

Pam3CSK4 As a Second Hit in NLRP3‐Dependent Activation of Monocytes Primed With Antiphospholipid Antibodies

open access: yesEuropean Journal of Immunology, Volume 56, Issue 7, July 2026.
Pam3CSK4 amplifies aPL‐induced monocyte activation. This results in thromboinflammatory activation that may contribute to APS‐related vascular pathology. ABSTRACT Antiphospholipid antibodies (aPL) are drivers of inflammation and thrombosis in antiphospholipid syndrome (APS). However, the molecular mechanisms underlying infection‐induced exacerbation of
Anush Martirosyan   +5 more
wiley   +1 more source

Etude de la thromboinflammation à la phase aigue de l'AVC ischémique: physiopathologie et nouvelles stratégies thérapeutiques

open access: yes
Ischemic stroke occurs when a cerebral artery is occluded by a thrombus and is a leading cause of death and disability worldwide. Risk factors such as diabetes and hypertension increase stroke incidence and severity. Recanalization is the only treatment:
Perrot, Astride
core   +2 more sources

Platelet aggregation responses to Salmonella Typhimurium are determined by host anti-Salmonella antibody levels

open access: yesPlatelets
Invasive non-typhoidal Salmonella infections are responsible for >75 000 deaths/year and >500 000 cases/year globally. Seventy-five percent of these cases occur in Sub-Saharan Africa, an increasing number of which are from multi-drug resistant strains ...
Rachel E Lamerton   +4 more
doaj   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1685-1695, June 2026.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy